Baricitinib + Placebo
Phase 2Completed 0 watching 0 views this week⚡ Active
52
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Systemic Lupus Erythematosus
Conditions
Systemic Lupus Erythematosus
Trial Timeline
Mar 24, 2016 → Nov 9, 2017
NCT ID
NCT02708095About Baricitinib + Placebo
Baricitinib + Placebo is a phase 2 stage product being developed by Eli Lilly for Systemic Lupus Erythematosus. The current trial status is completed. This product is registered under clinical trial identifier NCT02708095. Target conditions include Systemic Lupus Erythematosus.
Hype Score Breakdown
Clinical
17
Activity
12
Company
10
Novelty
5
Community
5
Clinical Trials (20)
| NCT ID | Phase | Status |
|---|---|---|
| NCT07222332 | Phase 3 | Recruiting |
| NCT07222137 | Phase 3 | Recruiting |
| NCT05237388 | Phase 2 | Recruiting |
| NCT05723198 | Phase 3 | Recruiting |
| NCT04421027 | Phase 3 | Completed |
| NCT03843125 | Phase 3 | Terminated |
| NCT03899259 | Phase 3 | Completed |
| NCT03742973 | Phase 2 | Terminated |
| NCT03773978 | Phase 3 | Completed |
| NCT03570749 | Phase 2/3 | Completed |
| NCT03616964 | Phase 3 | Completed |
| NCT03616912 | Phase 3 | Terminated |
| NCT03334435 | Phase 3 | Completed |
| NCT03435081 | Phase 3 | Completed |
| NCT03334422 | Phase 3 | Completed |
| NCT03334396 | Phase 3 | Completed |
| NCT02758613 | Phase 1 | Completed |
| NCT02708095 | Phase 2 | Completed |
| NCT02265705 | Phase 3 | Completed |
| NCT01885078 | Phase 3 | Completed |
Competing Products
20 competing products in Systemic Lupus Erythematosus